Zymeworks
Zymeworks is a clinical-stage biotechnology company developing novel biotherapeutics to treat diseases like cancer and autoimmune disorders. The company focuses on engineering antibody-based treatments and offers a dynamic work environment with opportunities for professional growth.
Headquarters
Vancouver, British Columbia, Canada
Company Size
201-500 employees
Founded
2003
Zymeworks is a royalty-driven biopharmaceutical organization developing novel medicines for patients with difficult-to-treat cancers and other serious diseases. Through proprietary antibody technology platforms, deep scientific expertise, and global partnerships, it builds and manages a portfolio of healthcare assets designed to deliver long-term impact across multiple therapeutic indications. Zymeworks advances both partnered and internal programs, including its FDA-approved product Ziihera® (zanidatamab-hrii), with a strategy centered on integrating collaborations to bring novel therapeutics to the broadest group of patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Zymeworks.
34% below the average for this role
Director, Radiopharmaceutical Imaging (RPI)
Bristol Myers Squibb
Senior Manager, Clinical Research Scientist
Genmab
Director, Regulatory Affairs Strategy
Arcellx
Medical Director - Clinical Development - Oncology
AbCellera
Head of Biostatistics
Zenas BioPharma
Executive Director, Medical Affairs
Artiva Biotherapeutics